T1	intervention 76 89	pegfilgrastim
T2	control 103 113	filgrastim
T3	ethinicity 117 124	Chinese
T4	eligibility 125 174	breast cancer patients receiving TAC chemotherapy
T5	location 799 804	China
T6	total-participants 814 817	171
T10	outcome 1431 1464	incidence of grade 3+ neutropenia
T12	outcome 1693 1708	safety profiles
T13	iv-cont-mean 1245 1249	2.09
T14	iv-cont-mean 1251 1255	1.53
T16	cv-cont-mean 1356 1365	1.69 days
T15	iv-cont-mean 1260 1269	1.73 days
T17	iv-bin-percent 1469 1471	76
T18	iv-bin-percent 1473 1475	83
T19	iv-bin-percent 1480 1484	74 %
T20	iv-bin-percent 1516 1520	90 %
T9	outcome 1565 1584	febrile neutropenia
T11	outcome 1586 1613	time to neutrophil recovery
T21	outcome 1618 1636	neutrophil profile
T22	outcome 1169 1206	mean duration of grade 3+ neutropenia
